Livzon Pharmaceutical approves governance changes, supervisory board abolished

Livzon Pharmaceutical Group held its first extraordinary general meeting of shareholders for 2025 on December 10, 2025, approving several key resolutions. The meeting, attended by 425 shareholders representing 50.9268% of total voting shares, passed proposals to abolish the supervisory board, amend the articles of association and rules for general meetings and board of directors, and revise the "Management System for Raised Funds." All proposals were approved.

Additionally, Ms. Wang Zhiyao was nominated as an independent non-executive director. The approval of these special resolutions, including the cancellation of the supervisory board and related amendments, reflects a significant restructuring of the company's governance framework. These changes aim to streamline operations and enhance the efficiency of the board.

The company's eleventh board of directors also met on December 10, 2025, to adjust its specialized committees. Mr. Bai Hua was appointed chairman of the audit committee, Ms. Cui Lijie became chair of the remuneration and assessment committee, and Mr. Luo Huiyuan will chair the nomination committee. The environment, social, and governance committee will be led by Mr. Zhu Baoguo, with no changes to the strategic committee.